Skip to main content
Glama

Compare Entities

compare_entities
Read-onlyIdempotent

"Compare X and Y" / "X vs Y" / "X versus Y" / "which is bigger / better / larger / more profitable" / "rank these companies" / "head to head" — side-by-side comparison of 2–5 companies or drugs in ONE parallel call. ALWAYS PREFER over sequential single-pack lookups when comparing entities. type="company" pulls LATEST 10-K revenue + net income + cash + long-term debt from SEC EDGAR/XBRL (off-calendar fiscal years handled correctly — AAPL Sep, NVDA Jan, etc.). type="drug" pulls FAERS adverse-event counts, FDA approval counts, active trial counts. Results sorted by primary metric so "largest" / "most" / "biggest" reads off the top of the response. Returns paired data + pipeworx:// citation URIs per entity. Replaces 8–15 sequential lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valuesYesFor company: 2–5 tickers/CIKs (e.g., ["AAPL","MSFT"]). For drug: 2–5 names (e.g., ["ozempic","mounjaro"]).

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. First observed

TDQS

A4.9/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Beyond the read-only/idempotent annotations, the description discloses data sources (SEC EDGAR/XBRL, FAERS), handles edge cases (off-calendar fiscal years), sort order by primary metric, and the return of paired data with citation URIs. It also states the efficiency gain ('Replaces 8–15 sequential lookups'), giving a complete behavioral picture without contradicting annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness5/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is dense but every sentence earns its place: trigger examples, preference rule, data source details for both types, sort behavior, return format, and efficiency claim. It is front-loaded with core purpose and structured to separate company vs drug specifics.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness4/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With no output schema, the description covers return style (paired data + citation URIs) and sorting, but does not fully specify the response schema (e.g., exact field names, metric definitions). Minor gap for a tool with two entity types and a ranking output, but sufficient for an agent to select and invoke it.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Even with 100% schema coverage, the description adds significant meaning to the `type` parameter by explaining what data each type fetches and how results are ordered. It also provides concrete examples for `values` (tickers/CIKs, drug names), enriching the schema's enum and array descriptions.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description opens with explicit example queries and states 'side-by-side comparison of 2–5 companies or drugs in ONE parallel call.' It clearly identifies the resource (companies/drugs) and distinguishes from sibling single-entity lookups by adding 'ALWAYS PREFER over sequential single-pack lookups when comparing entities.'

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It provides concrete trigger phrases ('Compare X and Y', 'X vs Y', 'rank these companies') and explicitly directs preference over sequential lookups. The description also differentiates behavior by type (company vs drug), giving users clear guidance on when each mode is appropriate.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.7/5.0
Disambiguation4/5

Most tools have clear, distinct purposes, especially within the same domain (e.g., Polymarket betting tools each serve a specific function). However, the multiple data-querying tools (ask_pipeworx, ask_pipeworx_grounded, deep_research) could cause confusion despite detailed descriptions.

Naming Consistency3/5

Many tools follow a verb_noun snake_case pattern (e.g., bet_research, compare_entities), but there are exceptions like ai_visibility_check, forget, and suggest_questions. The mix of imperative verbs and descriptive phrases creates inconsistency.

Tool Count2/5

With 35 tools, the server feels overloaded. While each domain (biomedical, financial, betting) is covered extensively, the sheer number of tools likely overwhelms agents, and many tools could be merged or split into separate servers.

Completeness4/5

The tool set is comprehensive for its declared purpose, covering biomedical queries, company data, betting analysis, memory management, and more. Minor gaps exist (e.g., no tool to delete a bet, no write operations for biomedical data), but the breadth is impressive.